Impact of Thyroid Hormone Receptor alpha Expression and PD-L1 on Progression-Free Survival of NSCLC Patients Treated with Pembrolizumab Immunotherapy
DOI:
https://doi.org/10.52783/jns.v14.1937Keywords:
Immunohistochemistry, PD-L1, THRα, NSCLC, ImmunotherapyAbstract
Lung cancer is categorized into small cell lung cancer and non-small cell lung cancer (NSCLC) based on histological distinctions. Pembrolizumab, an anti-programmed death-1 (PD-1) monoclonal antibody, is utilized for patients with NSCLC who exhibit modulation of the programmed death ligand (PD-L1) molecule. This study prospectively examined different patterns of Thyroid Hormone Receptor (THR) and PD-L1 immunohistochemical expression and their impact on the effectiveness of immunotherapy in improving progression-free survival (PFS) in 93 NSCLC patients. Variations were assessed according to histopathological subtype, TNM staging, tumor grade, Eastern Cooperative Oncology Group (ECOG) performance status, and other factors that may influence disease progression or treatment outcomes.
The mean age of patients was 59.97 years, comprising 26 females and 67 males. Among the 93 patients, 55 exhibited low PD-L1 expression (≤10%), while 38 patients exhibited high PD-L1 expression (>10%). THRα expression was observed at variable ratios, and the mean PFS was 48.9 weeks. A significant correlation was found between PD-L1 and THRα regarding PFS, with the highest PFS observed in patients exhibiting THRα expression levels between 26% and 50%, and the lowest PFS duration seen in patients with 76% to 100% THRα expression. The impact of PD-L1 expression on PFS duration increased with elevated levels of PD-L1 expression.
These findings demonstrate that THRα and PD-L1 expression are more prevalent in NSCLC patients, correlating with higher tumor grades, increased metastasis, and reduced ECOG performance status. The study found that the PFS of PD-L1-positive NSCLC patients treated with pembrolizumab was significantly better in those with 26% to 50% THR expression.
Downloads
Metrics
References
Padinharayil, Hafiza, Jinsu Varghese, Mithun Chacko John, Golgodu Krishnamurthy Rajanikant, Cornelia M. Wilson, Minnatallah Al-Yozbaki, Kaviyarasi Renu et al. "Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics." Genes & Diseases 10, no. 3 (2023): 960-989. sciencedirect.com.
Alduais, Y., Zhang, H., Fan, F., Chen, J., and Chen, B. "Non-small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment." Medicine (2023). lww.com
Zheng, Huili, Qimin Zhang, Yiru Gong, Zheyan Liu, and Shaohan Chen. "Identification of prognostic biomarkers for stage iii non-small cell lung carcinoma in female nonsmokers using machine learning." In 2024 5th International Conference on Big Data & Artificial Intelligence & Software Engineering (ICBASE), pp. 323-326. IEEE, 2024. [PDF].
Alexander, M., Kim, S. Y., and Cheng, H. "Update 2020: management of non-small cell lung cancer." Lung (2020). springer.com.
Takahara, Hirotomo, Takumi Kanazawa, Haruna Oshita, Yoshinobu Tomita, Yuri Hananoi, Sachiko Ishibashi, Masumi Ikeda et al. "GPX4 and FSP1 Expression in Lung Adenocarcinoma: Prognostic Implications and Ferroptosis-Based Therapeutic Strategies." Cancers 16, no. 22 (2024): 3888. mdpi.com.
Tan, Zhiwu, Mei Sum Chiu, Xinxiang Yang, Ming Yue, Tan To Cheung, Dongyan Zhou, Yuewen Wang et al. "Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients." Gut 72, no. 8 (2023): 1568-1580. [HTML].
Aranda, A. "Thyroid Hormone Action by Genomic and Nongenomic Molecular Mechanisms." Thyroid Hormones: Methods and Protocols (2024). [HTML].
Davri, Athena, Effrosyni Birbas, Theofilos Kanavos, Georgios Ntritsos, Nikolaos Giannakeas, Alexandros T. Tzallas, and Anna Batistatou. "Deep learning for lung cancer diagnosis, prognosis and prediction using histological and cytological images: a systematic review." Cancers 15, no. 15 (2023): 3981. mdpi.com.
Bie, Fenglong, He Tian, Nan Sun, Ruochuan Zang, Moyan Zhang, Peng Song, Lei Liu et al. "Research progress of anti-PD-1/PD-L1 immunotherapy related mechanisms and predictive biomarkers in NSCLC." Frontiers in Oncology 12 (2022): 769124. frontiersin.org.
Ritter, M. J., Amano, I., and Hollenberg, A. N. "Transcriptional Cofactors for Thyroid Hormone Receptors." Endocrinology (2025). [HTML].
Tambones, I. and le Maire, A. "Structural insights into thyroid hormone receptors." Endocrinology (2025). researchgate.net.
Sagliocchi, Serena, Federica Restolfer, Alessandro Cossidente, and Monica Dentice. "The key roles of thyroid hormone in mitochondrial regulation, at interface of human health and disease." Journal of Basic and Clinical Physiology and Pharmacology 35, no. 4-5 (2024): 231-240. degruyter.com.
Contreras-Jurado, S. C. "Thyroid Hormones and Co-workers: An Overview." Thyroid Hormones: Methods and Protocols (2024). [HTML]
Blanco, Remei, Manuel Dómine, José Luis González, Sami Loutfi, Jordi Alfaro, Juana Saldaña, Jaime Rubio et al. "Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes." Lung Cancer 183 (2023): 107318. sciencedirect.com.
Boruah, Monikongkona, Pranitha Gaddam, Shipra Agarwal, Riyaz Ahmad Mir, Ranjan Gupta, Mehar C. Sharma, Suryanarayana VS Deo, and Nilima Nilima. "PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy." Journal of Cancer Research and Therapeutics 19, no. 2 (2023): 312-320. lww.com.
Gillis, Noelle E., Lauren M. Cozzens, Emily R. Wilson, Noah M. Smith, Jennifer A. Tomczak, Eric L. Bolf, and Frances E. Carr. "TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice." Endocrinology 164, no. 10 (2023): bqad135. nih.gov.
Deutsch, Julie Stein, Ashley Cimino-Mathews, Elizabeth Thompson, Mariano Provencio, Patrick M. Forde, Jonathan Spicer, Nicolas Girard et al. "Association between pathologic response and survival after neoadjuvant therapy in lung cancer." Nature medicine 30, no. 1 (2024): 218-228. nature.com.
Emily Z Keung and Jeffrey E Gershenwald (The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care) PMC: 2020 Nov 9.doi: 10.1080/14737140.2018.1489246.
Cai, C., Zhou, S., Qu, J., and Zhou, J. "Immune-related thyroid dysfunction in patients with non-small cell lung cancer." Journal of Thoracic Disease (2024). nih.gov
Succony, L., D. M. Rassl, A. P. Barker, F. M. McCaughan, and R. C. Rintoul. "Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies." Cancer treatment reviews 99 (2021): 102237. [HTML].
Darragh, L. B. "Improving Response to Immunotherapy in Head and Neck Squamous Cell Carcinoma by Reducing Nodal Irradiation." (2023). [HTML].
Chu, X., Tian, W., Wang, Z., Zhang, J., and Zhou, R. "Co-inhibition of TIGIT and PD-1/PD-L1 in cancer immunotherapy: mechanisms and clinical trials." Molecular cancer (2023). springer.com.
de Rodas, Miguel Lopez, Venkata Nagineni, Arvind Ravi, Ila J. Datar, Mari Mino-Kenudson, German Corredor, Cristian Barrera et al. "Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer." Journal for immunotherapy of cancer 10, no. 6 (2022). nih.gov.
Abdulameer K. Leelo1 and Hawraa A. K. Leelo, Immunohistochemical Expression of TGF-β1 and Ki-67 in a Paraffin-Embedded Section of Breast Cancer Tissue, Indian Journal of Forensic Medicine & Toxicology, October-December 2019, Vol. 13, No. 4 p 1134- 1139 DOI Number: 10.5958/0973-9130.2019.00453.5
Francisco-Cruz, Alejandro, Pedro Rocha, Alexandre Reuben, Santhoshi N. Krishnan, Priyam Das, Runzhe Chen, Kelly Quek et al. "Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non–Small Cell Lung Cancer." Modern Pathology 36, no. 1 (2023): 100028. sciencedirect.com.
Nikolaus John, Verena Schlintl,Teresa Sassmann, Jörg Lindenmann, Melanie Fediuk, Robert Wurm,Philipp Douschan, Martin Zacharias, Lipika Kalson, Florian Posch, Gudrun Absenger, Luka Brcic,Philipp J Jost and Angelika Terbuch , Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC, J Immunother Cancer 2024;12:e008592. doi:10.1136/jitc-2023-008592.
Marletta, S.; Fusco, N.; Munari, E.; Luchini, C.; Cimadamore, A.; Brunelli, M.; Querzoli, G.; Martini, M.; Vigliar, E.; and Colombari, . Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. J. Pers. Med. 2022, 12, 1073.
Yatabe, Y.; Hirsch, F.R. The IASLC Atlas of PD-L1 Testing in Lung Cancer. 2017. Available online: https://www.iaslc.org/research-education/publications-resources-guidelines/iaslc-atlas-pd-l1-testing-lung-cancer (accessed on 15 October 2017).
Huang, Yiqing, Yu Yang Soon, Folefac Aminkeng, Sen Hee Tay, Yvonne Ang, Adrian CL Kee, Boon Cher Goh, Alvin SC Wong, and Ross A. Soo. "Risk factors for immune‐related adverse events from anti‐PD‐1 or anti‐PD‐L1 treatment in an Asian cohort of nonsmall cell lung cancer patients." International Journal of Cancer 150, no. 4 (2022): 636-644. [HTML]
Wu, Hui, Wenzhi Shu, Yongfeng Ding, Qiong Li, Ning Li, Qiyue Wang, Yinqi Chen, Yuejun Han, Dongdong Huang, and Haiping Jiang. "The Immune Signatures Predict Gastric/Gastroesophageal Junction Cancer Response to First-line Anti-PD-1 Blockade or Chemotherapy: Clinical and Multiplex Immunofluorescence Analysis." (2024). researchsquare.com.
Han, Zhongyu, Liuyan Chen, Hongyao Peng, Hongying Zheng, Yumeng Lin, Fang Peng,and Yunhe Fan et al. "The role of thyroid hormone in the renal immune microenvironment." International immunopharmacology 119 (2023): 110172. [HTML]
Trinity Quan ,Jessica Cockburn ,Sukhbinder Dhesy-Thind , Christopher Geleff, Anita Bane, Hon Leong ,Catherine Devion , Noor Ajel and Katarzyna J. Jerzak The Significance of Thyroid Hormone Receptors in Breast Cancer: A Hypothesis-Generating Narrative Review Curr. Oncol. 2024, 31(5), 2364-2375; https://doi.org/10.3390/curroncol31050176 .
Doghish, Ahmed S., Ahmed Ismail, Mahmoud A. Elrebehy, Abdullah MM Elbadry, Hend H. Mahmoud, Salma M. Farouk, Ghada A. Abu Serea et al. "A study of miRNAs as cornerstone in lung cancer pathogenesis and therapeutic resistance: A focus on signaling pathways interplay." Pathology-Research and Practice 237 (2022): 154053. [HTML].
Lai, Xin, Quanwei Chen, Xiaopeng Tang, Yuanqiang Zhou, Furong Gao, Yue Guo, Rohit Bhagat, and Yuejiu Zheng. "Critical review of life cycle assessment of lithium-ion batteries for electric vehicles: A lifespan perspective." Etransportation 12 (2022): 100169. [HTML]
Fabbri, Marco, Alessia Beracci, Monica Martoni, Debora Meneo, Lorenzo Tonetti, and Vincenzo Natale. "Measuring subjective sleep quality: a review." International journal of environmental research and public health 18, no. 3 (2021): 1082. mdpi.com.
Fanny, Viktoria Balntzi, Stuart R. Gray, Jose Lara, Frederick K. Ho, Jill P. Pell, and Carlos Celis‐Morales. "Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta‐analysis." Journal of cachexia, sarcopenia and muscle 13, no. 1 (2022): 86-99. wiley.com.
Du , Qinyun, Jiayi Sun, Li Xiang, and Shaohui Wang. "novel phagocytosis regulators-related signature with potential." Novel Biomarkers for Potential Clinical Applications in Lung Cancer (2024): 123. [HTML].
Førde, Dagny, Thomas Kilvær, Mona Irene Pedersen, Egil S. Blix, Ilona Urbarova, Erna-Elise Paulsen, Mehrdad Rakaee, Lill-Tove Rasmussen Busund, Tom Donnem, and Sigve Andersen. "High density of TCF1+ stem-like tumor-infiltrating lymphocytes is associated with favorable disease-specific survival in NSCLC." Frontiers in Immunology 15 (2024): 1504220. frontiersin.org.
Forster, Martin, Irene Brana, Antonio L. Pousa, Bernard Doger, Patricia Roxburgh, Pawan Bajaj, Julio Peguero et al. "Eftilagimod alpha (soluble LAG3 protein) combined with pembrolizumab as second-line therapy for patients with metastatic head and neck squamous cell carcinoma." Clinical Cancer Research 30, no. 17 (2024): 3726-3734. [HTML].
Fu, Hanlin, Zhihui Fu, Meng Mao, Lulu Si, Jing Bai, Qian Wang, and Ruixia Guo. "Prevalence and prognostic role of PD-L1 in patients with gynecological cancers: A systematic review and meta-analysis." Critical Reviews in Oncology/Hematology (2023): 104084. sciencedirect.com
Nicholas, Ben, Alistair Bailey, Katy J. McCann, Peter Johnson, Tim Elliott, Christian Ottensmeier, and Paul Skipp. "Comparative analysis of transcriptomic and proteomic expression between two non-small cell lung cancer subtypes." Journal of Proteome Research (2025). acs.org.
Lu, Yiran, Qingchen Li, Lusi Xu, Yanqing Zheng, Yanchao Wang, Ying Liu, Rui Zhang, Lin Liao, and Jianjun Dong. "Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma." Journal of Cancer Research and Clinical Oncology 149, no. 18 (2023): 16501-16510. springer.com.
Lim, Sun M., Seong-san Kang, Dong K. Kim, Soo-Hwan Lee, Chun-Bong Synn, Sujeong Baek, Seung M. Yang et al. "Exploration of immune-modulatory effects of Amivantamab in combination with pembrolizumab in lung and head and neck squamous cell carcinoma." Cancer Research Communications 4, no. 7 (2024): 1748-1764. aacrjournals.org.
Hao, J., Wang, S., Wang, J., Zhang, Z., Gao, M., and Wan, Y. "A novel autophagy-related long non-coding RNAs signature predicting progression-free interval and I-131 therapy benefits in papillary thyroid carcinoma." Open Medicine (2023). degruyter.com.
Wei, Xiao-Chen, Yuan-Yuan Guo, Yi Zhang, Yi-Shan Bu, and Feng-Ying Zhang. "Factors associated with immune-related thyroid dysfunction induced by PD-1/PD-L1 inhibitors in cancer patients: an observational study." Journal of Chemotherapy (2024): 1-8. [HTML].
Wang, Y., Yang, X., Ma, J., Chen, S., Gong, P., and Dai, P. "Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer." Heliyon (2024). cell.com.
Zhu, Zhaoyang, Yigang Jin, Jing Zhou, Fei Chen, Minjie Chen, Zhaofeng Gao, Lingyu Hu et al. "PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives." Molecular Cancer 23, no. 1 (2024): 146. springer.com.
Yoon, Jee Hee, A. Ram Hong, Hee Kyung Kim, and Ho-Cheol Kang. "Characteristics of immune-related thyroid adverse events in patients treated with PD-1/PD-L1 inhibitors." Endocrinology and Metabolism 36, no. 2 (2021): 413-423. koreamed.org.
Quan, Trinity, Jessica Cockburn, Sukhbinder Dhesy-Thind, Anita Bane, Hon Leong, Christopher Geleff, Catherine Devion, Noor Ajel, and Katarzyna J. Jerzak. "The Significance of Thyroid Hormone Receptors in Breast Cancer: A Hypothesis-Generating Narrative Review." Current Oncology 31, no. 5 (2024): 2364-2375. mdpi.com.
Kannan, Balachander, Chandra Pandi, Anitha Pandi, Vijayashree Priyadharsini Jayaseelan, and Paramasivam Arumugam. "Triggering receptor expressed in myeloid cells 1 (TREM1) as a potential prognostic biomarker and association with immune infiltration in oral squamous cell carcinoma." Archives of Oral Biology 161 (2024): 105926. [HTML].
Larroquette, Mathieu, Jean-Philippe Guegan, Benjamin Besse, Sophie Cousin, Maxime Brunet, Sylvestre Le Moulec, François Le Loarer et al. "Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies." Journal for ImmunoTherapy of Cancer 10, no. 5 (2022). nih.gov.
Leiter, Amanda, Rajwanth R. Veluswamy, and Juan P. Wisnivesky. "The global burden of lung cancer: current status and future trends." Nature reviews Clinical oncology 20, no. 9 (2023): 624-639. ns-svc.cn.
Macerola, Elisabetta, Anello Marcello Poma, Paola Vignali, Agnese Proietti, Clara Ugolini, Liborio Torregrossa, Alessio Basolo, Rossella Elisei, Ferruccio Santini, and Fulvio Basolo. "Predictive biomarkers in thyroid cancer." Frontiers in Oncology 12 (2022): 901004. frontiersin.org.
Medić-Milijić, Nataša, Irena Jovanić, Milica Nedeljković, Ivan Marković, Igor Spurnić, Zorka Milovanović, Nejla Ademović, Tijana Tomić, Nasta Tanić, and Nikola Tanić. "Prognostic and Clinical Significance of PD-L1, EGFR and Androgen Receptor (AR) Expression in Triple-Negative Breast Cancer (TNBC) Patients." Life 14, no. 6 (2024): 682. mdpi.comLi, Haiyan, Sunitha Shyam Sunder, Karan Jatwani, Yongho Bae, Lei Deng, Qian Liu, Grace K. Dy, and Saraswati Pokharel. "Tumor Characteristics and Treatment Responsiveness in Pembrolizumab-Treated Non-Small Cell Lung Carcinoma." Cancers 16, no. 4 (2024): 744. mdpi.com.
Manna, Lorenzo, Rosa Rapuano Lembo, Asami Yoshioka, Koji Nakamura, Margherita Passariello, and Claudia De Lorenzo. "A comparison of the antitumor efficacy of novel multi-specific Tribodies with combinations of approved immunomodulatory antibodies." Cancers 15, no. 22 (2023): 5345. mdpi.com.
Matsuki, Takashi, Daisuke Kawakita, Hideaki Takahashi, Takuro Okada, Akihiro Sakai, Yushi Ueki, Hiroshi Tsuge et al. "PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab." Scientific Reports 14, no. 1 (2024): 19794. nature.com.
Nelli, Fabrizio, Enzo Maria Ruggeri, Marta Schirripa, Antonella Virtuoso, Diana Giannarelli, Armando Raso, Daniele Remotti, and Agnese Fabbri. "Longitudinal Assessment of FT3 to FT4 Conversion Ratio in Predicting the Efficacy of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small Cell Lung Cancer: A Propensity-Score Matching Analysis of Data from the National Drug Monitoring Agency." Current Oncology 31, no. 12 (2024): 7647-7662. mdpi.com.
Nesline, Mary K., Rebecca A. Previs, Grace K. Dy, Lei Deng, Yong Hee Lee, Paul DePietro, Shengle Zhang et al. "PD-L1 expression by RNA-sequencing in non-small cell lung cancer: concordance with immunohistochemistry and associations with pembrolizumab treatment outcomes." Cancers 15, no. 19 (2023): 4789. mdpi.com.
Pfister, David G., Robert I. Haddad, Francis P. Worden, Jared Weiss, Ranee Mehra, Laura QM Chow, Stephen V. Liu et al. "Biomarkers predictive of response to pembrolizumab in head and neck cancer." Cancer medicine 12, no. 6 (2023): 6603-6614. wiley.com.
Rodas, Miguel Lopez, Venkata Nagineni, Arvind Ravi, Ila J. Datar, Mari Mino-Kenudson, German Corredor, Cristian Barrera et al. "Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer." Journal for immunotherapy of cancer 10, no. 6 (2022). nih.gov.
Rudin, Charles M., Elisabeth Brambilla, Corinne Faivre-Finn, and Julien Sage. "Small-cell lung cancer." Nature Reviews Disease Primers 7, no. 1 (2021): 3. nih.gov.
Elkady, G., Sayed, A., Priya, S., Nagarjuna, B., Haralayya, B., & Aarif, M. (2024). An Empirical Investigation into the Role of Industry 4.0 Tools in Realizing Sustainable Development Goals with Reference to Fast Moving Consumer Foods Industry. In Advanced Technologies for Realizing Sustainable Development Goals: 5G, AI, Big Data, Blockchain, and Industry 4.0 Application (pp. 193-203). Bentham Science Publishers.
Nimma, D., Kaur, C., Chhabra, G., Selvi, V., Tyagi, D., & Balakumar, A. (2024, December). Optimizing Mobile Advertising with Reinforcement Learning and Deep Neural Networks. In 2024 International Conference on Artificial Intelligence and Quantum Computation-Based Sensor Application (ICAIQSA) (pp. 1-6). IEEE.
Katrawi, Anwar & Abdullah, Rosni & Anbar, Mohammed & Alshourbaji, Ibrahim & Abasi, Ammar. (2021). Straggler handling approaches in mapreduce framework: a comparative study Corresponding Author. International Journal of Electrical and Computer Engineering (IJECE). 11. 375-382. 10.11591/ijece.v11i1.pp375-382.
Elkady, G., Sayed, A., Mukherjee, R., Lavanya, D., Banerjee, D., & Aarif, M. (2024). A Critical Investigation into the Impact of Big Data in the Food Supply Chain for Realizing Sustainable Development Goals in Emerging Economies. In Advanced Technologies for Realizing Sustainable Development Goals: 5G, AI, Big Data, Blockchain, and Industry 4.0 Application (pp. 204-214). Bentham Science Publishers.
Kaur, C., Al Ansari, M. S., Rana, N., Haralayya, B., Rajkumari, Y., & Gayathri, K. C. (2024). A Study Analyzing the Major Determinants of Implementing Internet of Things (IoT) Tools in Delivering Better Healthcare Services Using Regression Analysis. In Advanced Technologies for Realizing Sustainable Development Goals: 5G, AI, Big Data, Blockchain, and Industry 4.0 Application (pp. 270-282). Bentham Science Publishers.
Patel, Ahmed & Alshourbaji, Ibrahim & Al-Janabi, Samaher. (2014). Enhance Business Promotion for Enterprises with Mashup Technology. Middle East Journal of Scientific Research. 22. 291-299.
Praveena, K., Misba, M., Kaur, C., Al Ansari, M. S., Vuyyuru, V. A., & Muthuperumal, S. (2024, July). Hybrid MLP-GRU Federated Learning Framework for Industrial Predictive Maintenance. In 2024 Third International Conference on Electrical, Electronics, Information and Communication Technologies (ICEEICT) (pp. 1-8). IEEE.
Alshourbaji, Ibrahim & Al-Janabi, Samaher & Patel, Ahmed. (2016). Document Selection in a Distributed Search Engine Architecture. 10.48550/arXiv.1603.09434.
Kaur, C., Al Ansari, M. S., Dwivedi, V. K., & Suganthi, D. (2024). Implementation of a Neuro‐Fuzzy‐Based Classifier for the Detection of Types 1 and 2 Diabetes. Advances in Fuzzy‐Based Internet of Medical Things (IoMT), 163-178.
Alijoyo, F. A., Prabha, B., Aarif, M., Fatma, G., & Rao, V. S. (2024, July). Blockchain-Based Secure Data Sharing Algorithms for Cognitive Decision Management. In 2024 International Conference on Electrical, Computer and Energy Technologies (ICECET (pp. 1-6). IEEE.
Sharma, R., Singh, D. K., Kumar, P., Khalid, M., Dash, T. R., Vij, B., ... & Kishan, R. THIRD IEEE TECHNICAL SPONSORED INTERNATIONAL CONFERENCE ON SMART TECHNOLOGES AND SYSTEMS FOR NEXT GENERATION COMPUTING (ICSTSN 2024).
Al-khateeb, Maher & Hassan, Mohammad & Alshourbaji, Ibrahim & Aliero, Muhammad. (2021). Intelligent Data Analysis approaches for Knowledge Discovery: Survey and challenges. İlköğretim Online. 20. 1782-1792. 10.17051/ilkonline.2021.05.196.
Tripathi, M. A., Goswami, I., Haralayya, B., Roja, M. P., Aarif, M., & Kumar, D. (2024). The Role of Big Data Analytics as a Critical Roadmap for Realizing Green Innovation and Competitive Edge and Ecological Performance for Realizing Sustainable Goals. In Advanced Technologies for Realizing Sustainable Development Goals: 5G, AI, Big Data, Blockchain, and Industry 4.0 Application (pp. 260-269). Bentham Science Publishers.
Ravichandran, K., Virgin, B. A., Patil, S., Fatma, G., Rengarajan, M., & Bala, B. K. (2024, July). Gamifying Language Learning: Applying Augmented Reality and Gamification Strategies for Enhanced English Language Acquisition. In 2024 Third International Conference on Smart Technologies and Systems for Next Generation Computing (ICSTSN) (pp. 1-6). IEEE.
Preethi, T., Anjum, A., Ahmad, A. A., Kaur, C., Rao, V. S., El-Ebiary, Y. A. B., & Taloba, A. I. (2024). Advancing Healthcare Anomaly Detection: Integrating GANs with Attention Mechanisms. International Journal of Advanced Computer Science & Applications, 15(6).
Rajkumari, Y., Jegu, A., Fatma, G., Mythili, M., Vuyyuru, V. A., & Balakumar, A. (2024, October). Exploring Neural Network Models for Pronunciation Improvement in English Language Teaching: A Pedagogical Perspective. In 2024 International Conference on Intelligent Systems and Advanced Applications (ICISAA) (pp. 1-6). IEEE.
Alim, Sophia & Alshourbaji, Ibrahim. (2020). Professional uses of Facebook amongst university students in relation to searching for jobs: an exploration of activities and behaviours. International Journal of Social Media and Interactive Learning Environments. 6. 200-229. 10.1504/IJSMILE.2020.10031269.
Orosoo, M., Rajkumari, Y., Ramesh, K., Fatma, G., Nagabhaskar, M., Gopi, A., & Rengarajan, M. (2024). Enhancing English Learning Environments Through Real-Time Emotion Detection and Sentiment Analysis. International Journal of Advanced Computer Science & Applications, 15(7).
Tripathi, M. A., Singh, S. V., Rajkumari, Y., Geethanjali, N., Kumar, D., & Aarif, M. (2024). The Role of 5G in Creating Smart Cities for Achieving Sustainable Goals: Analyzing the Opportunities and Challenges through the MANOVA Approach. Advanced Technologies for Realizing Sustainable Development Goals: 5G, AI, Big Data, Blockchain, and Industry 4.0 Application, 77-86.
Sharma, M., Chinmulgund, A., Kuanr, J., & Fatma, G. (2024, April). The Future of Teaching: Exploring the Integration of Machine Learning in Higher Education. In 2024 International Conference on Knowledge Engineering and Communication Systems (ICKECS) (Vol. 1, pp. 1-6). IEEE.
Shiotsu, Shinsuke, Akihiro Yoshimura, Tadaaki Yamada, Kenji Morimoto, Michiko Tsuchiya, Hiroshige Yoshioka, Osamu Hiranuma et al. "Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study." Frontiers in Oncology 12 (2022): 904644. frontiersin.org.
Song, Lianxi, Liang Zeng, Huan Yan, Qinqin Xu, Qing Xia, Jian Lei, Xiaoyan Chen et al. "Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer." Communications Medicine 2, no. 1 (2022): 137. nature.com.
Sun, J., Liu, J., Wu, T., Gu, Z., and Zhang, X. "Sensitivity to thyroid hormone indices are associated with papillary thyroid carcinoma in Chinese patients with thyroid nodules." BMC Endocrine Disorders (2023). springer.com.
Tang, Qing, Yun Chen, Xiaojuan Li, Shunqin Long, Yao Shi, Yaya Yu, Wanyin Wu, Ling Han, and Sumei Wang. "The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers." Frontiers in immunology 13 (2022): 964442. frontiersin.org.
Rakaee, Mehrdad, S. Andersen, K. Giannikou, E-E. Paulsen, Thomas Karsten Kilvær, L-TR Busund, Thomas Berg et al. "Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial." Annals of Oncology 34, no. 7 (2023): 578-588. sciencedirect.com.
Wu, Shugui, Shanlian Wu, Xiaohong Liao, Chaoming Zhou, Feng Qiu, Chen Wang, and Wenjuan Zhong. "Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review." Frontiers in Immunology 14 (2023): 1274937. frontiersin.org.
Zheng, X., Chen, X., and Wu, W. "The Regulatory Axis of PD-L1 Isoform 2/TNF/T Cell Proliferation Is Required for the Canonical Immune-Suppressive Effects of PD-L1 Isoform 1 in Liver Cancer." International Journal of Molecular Sciences (2023). mdpi.com.
Yu, Hui, Ping Chen, Xiuyu Cai, Chen Chen, Xuanye Zhang, Lina He, Yixin Zhou, Shaodong Hong, and Bei Zhang. "Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer." Cancer Immunology, Immunotherapy 71, no. 3 (2022): 637-644. nih.gov.
Thuillier, P., Joly, C., Alavi, Z., and Crouzeix…, G. "Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an …." Cancer Immunology … (2021). nih.gov.
van den Ende, Nadine S., Anh H. Nguyen, Agnes Jager, Marleen Kok, Reno Debets, and Carolien HM van Deurzen. "Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review." International Journal of Molecular Sciences 24, no. 3 (2023): 2969. mdpi.com
van der Woude, Lieke L., Mark AJ Gorris, Inge MN Wortel, Jeroen HA Creemers, Kiek Verrijp, Kim Monkhorst, Katrien Grünberg et al. "Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination." Journal for ImmunoTherapy of Cancer 10, no. 10 (2022). nih.gov.
Wang, Rong, Shiwei He, Jun Long, Yian Wang, Xianjie Jiang, Mingfen Chen, and Jie Wang. "Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways." Experimental Hematology & Oncology 13, no. 1 (2024): 46. springer.com.
Wu, Hui, Wenzhi Shu, Yongfeng Ding, Qiong Li, Ning Li, Qiyue Wang, Yinqi Chen, Yuejun Han, Dongdong Huang, and Haiping Jiang. "The Immune Signatures Predict Gastric/Gastroesophageal Junction Cancer Response to First-line Anti-PD-1 Blockade or Chemotherapy: Clinical and Multiplex Immunofluorescence Analysis." (2024). researchsquare.com.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
